-
Merck KGaA pulls plug on cladribine on FDA feedback
(Reuters) – Merck KGaA said U.S. drug regulators’ concerns about the risks of its cladribine pill will put an end to any development or marketing plans for [...]
-
HOT off the CMSC Press: Rebif at first sign of MS delays progression
Starting interferon-beta-1a (Rebif New Formulation) immediately upon an episode of a clinically isolated syndrome delayed progression to full-blown multiple sclerosis, but once-weekly treatment was less effective than [...]
-
HOT off the CMSC Press: Fatigue often the first MS symptom
MONTREAL — Months or even years before demyelinating events are recognized, patients later diagnosed with multiple sclerosis often turn up in their doctors’ offices complaining of fatigue, [...]
-
Stem cell funding ban overturned in the US
In a 2-1 decision, a panel of the court of appeals in Washington overturned a judge’s order that would have blocked federal financing of stem cell research. [...]
-
Scientists Have (Potentially) Discovered the Chemical that Triggers MS
Scientists are said to have made a major breakthrough as they have found the chemical that enhances the symptoms of multiple sclerosis. The chemical known as granulocyte-macrophage [...]
-
FDA details timeframe of Tysabri’s PML risk
The brain infection risk from Biogen Idec’s multiple sclerosis drug Tysabri appears highest during the third year of treatment, U.S. health officials said in an updated warning [...]
-
HOT off the AAN 2011 Press: Lemtrada (alemtuzumab) shines over Rebif in clinical trials
Five years’ worth of mid-stage data for Lemtrada (alemtuzumab) showed that 65% of patients were free of clinically-active disease, compared to 27% on Merck’s interferon treatment Rebif. [...]
-
IF YOU CAN DREAM: Upcoming Documentary Highlights Living and Thriving with MS
Over half a million Americans have been diagnosed with Multiple Sclerosis. The news can mean a life interrupted, and a dream dashed. Several films have highlighted a [...]
-
HOT off the AAN 2011 Press: 23% Lower Relapse Rate For MS Patients On Laquinimod
Multiple sclerosis patients on laquinimod experienced a 23% reduction in annual relapse rate compared to those on a placebo during a two year Phase III clinical trial [...]
-
HOT off the AAN 2011 Press: Biogen MS drug meets main goal in late-stage study
Biogen Idec Inc’s experimental multiple sclerosis drug met the main goal in the first of two important late-stage studies, the U.S. biotechnology company said on Monday. The [...]
